Plus Net Income From Continuing Ops from 2010 to 2026
| PSTV Stock | USD 0.26 0.03 13.04% |
Net Loss | First Reported 2014-03-31 | Previous Quarter 5.2 M | Current Value -4.4 M | Quarterly Volatility 4.9 M |
Check Plus Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Plus Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 2.3 M, Selling General Administrative of 10.1 M or Selling And Marketing Expenses of 637 K, as well as many indicators such as Price To Sales Ratio of 1.12, Dividend Yield of 0.0 or Days Sales Outstanding of 42.94. Plus financial statements analysis is a perfect complement when working with Plus Therapeutics Valuation or Volatility modules.
Plus | Net Income From Continuing Ops | Build AI portfolio with Plus Stock |
The evolution of Net Income From Continuing Ops for Plus Therapeutics provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Plus Therapeutics compares to historical norms and industry peers.
Latest Plus Therapeutics' Net Income From Continuing Ops Growth Pattern
Below is the plot of the Net Income From Continuing Ops of Plus Therapeutics over the last few years. It is Plus Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Plus Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Net Income From Continuing Ops | 10 Years Trend |
|
Net Income From Continuing Ops |
| Timeline |
Plus Net Income From Continuing Ops Regression Statistics
| Arithmetic Mean | (18,839,626) | |
| Coefficient Of Variation | (43.98) | |
| Mean Deviation | 6,631,294 | |
| Median | (18,744,000) | |
| Standard Deviation | 8,285,830 | |
| Sample Variance | 68.7T | |
| Range | 34.1M | |
| R-Value | 0.65 | |
| Mean Square Error | 41.9T | |
| R-Squared | 0.43 | |
| Significance | 0 | |
| Slope | 1,072,877 | |
| Total Sum of Squares | 1098.5T |
Plus Net Income From Continuing Ops History
About Plus Therapeutics Financial Statements
Plus Therapeutics investors use historical fundamental indicators, such as Plus Therapeutics' Net Income From Continuing Ops, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Plus Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Net Loss | -14.9 M | -15.7 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Plus Stock Analysis
When running Plus Therapeutics' price analysis, check to measure Plus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Plus Therapeutics is operating at the current time. Most of Plus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Plus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Plus Therapeutics' price. Additionally, you may evaluate how the addition of Plus Therapeutics to your portfolios can decrease your overall portfolio volatility.